Rezonic FDA Approval Status
FDA Approved: No
Brand name: Rezonic
Generic name: casopitant
Company: GlaxoSmithKline
Treatment for: Nausea/Vomiting, Chemotherapy Induced, Nausea/Vomiting, Postoperative
Rezonic (casopitant) is an investigational NK-1 receptor antagonist in development as add-on therapy for the prevention of chemotherapy-induced nausea and vomiting, and also for the prevention of postoperative nausea and vomiting.
Development timeline for Rezonic
| Date | Article |
|---|---|
| Sep 28, 2009 | GSK Provides Update on Regulatory Filings for Zunrisa/Rezonic |
| May 29, 2008 | GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic/Zunrisa (Casopitant) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
